CorMedix Inc (NASDAQ:CRMD - Get Free Report) Director Steven Lefkowitz acquired 11,500 shares of the firm's stock in a transaction that occurred on Wednesday, November 18th. The stock was acquired at an average price of $4.53 per share, with a total value of $52,095.00. Following the completion of the acquisition, the director directly owned 137,451 shares of the company's stock, valued at $622,653.03. This represents a 9.13% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.
CorMedix Price Performance
NASDAQ CRMD traded up $0.17 during trading hours on Friday, reaching $5.25. 2,060,039 shares of the company's stock were exchanged, compared to its average volume of 1,641,412. The stock has a market cap of $417.19 million, a PE ratio of 7.60, a price-to-earnings-growth ratio of 1.03 and a beta of 1.48. CorMedix Inc has a one year low of $4.47 and a one year high of $13.02. The firm has a fifty day moving average of $6.91 and a 200-day moving average of $7.50. The company has a current ratio of 2.43, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31.
CorMedix (NASDAQ:CRMD - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 26.70%. The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. On average, equities research analysts predict that CorMedix Inc will post 0.44 earnings per share for the current fiscal year.
Institutional Trading of CorMedix
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in CorMedix during the 2nd quarter valued at approximately $49,644,000. American Century Companies Inc. lifted its stake in CorMedix by 688.5% in the third quarter. American Century Companies Inc. now owns 2,722,920 shares of the company's stock worth $20,966,000 after acquiring an additional 2,377,579 shares during the period. Goldman Sachs Group Inc. boosted its holdings in CorMedix by 167.9% in the third quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company's stock valued at $9,620,000 after acquiring an additional 782,989 shares in the last quarter. Marshall Wace LLP boosted its holdings in CorMedix by 53.4% in the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company's stock valued at $9,205,000 after acquiring an additional 415,887 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in CorMedix by 128.7% during the 1st quarter. Pacer Advisors Inc. now owns 580,620 shares of the company's stock valued at $3,942,000 after purchasing an additional 326,724 shares during the period. Hedge funds and other institutional investors own 34.18% of the company's stock.
Wall Street Analyst Weigh In
CRMD has been the subject of several recent analyst reports. Citigroup reaffirmed a "market outperform" rating on shares of CorMedix in a research report on Tuesday, November 10th. Royal Bank Of Canada boosted their target price on shares of CorMedix from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Tuesday, November 10th. Needham & Company LLC upped their price target on shares of CorMedix from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, November 10th. Wall Street Zen lowered shares of CorMedix from a "hold" rating to a "sell" rating in a research report on Saturday, November 14th. Finally, UBS Group set a $19.00 price objective on shares of CorMedix in a research note on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.22.
Read Our Latest Stock Report on CorMedix
CorMedix Company Profile
(
Get Free Report)
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.